EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2

Mengqi Wang, Shuping Yang, Xinge Li, Yingying Zheng, Yan Bai, Wenhan Luo, Gongming Zhu, Junbiao Chang iD, Bo Zhu iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c01434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Mengqi Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, NMPA Key Laboratory for Research and Evaluation of Innovative Drug, School of Chemistry…. Hauptthemen laut MEDLINE: Urea, Antineoplastic Agents, Imidazoles, Apoptosis. Die Arbeit nennt 63 Literaturangaben. Gefördert von: Central Plains Scholars and Scientists Studio Fund, Henan Key Laboratory of Organic Functional Molecules and Drug Innovation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracellular signal-regulated kinases (ERKs) are pivotal signaling molecules in the RAS-RAF-MEK-ERK signaling pathway and have emerged as potential antitumor targets, providing a promising strategy for tumor therapy. Therefore, the development of antitumor drugs targeting ERK protein has received extensive attention. Here, we developed a compound library based on a series of novel aromatic urea-imidazole salt derivatives and conducted phenotypic screening against various cancer cell lines. Notably, 21y exhibited high efficacy against MCF-7 cells (IC50 = 0.67 μM). Furthermore, label-free drug affinity responsive target stability (DARTS) and LC-MS/MS proteomics techniques revealed that 21y directly targets ERK1/2. Mechanistically, 21y induced cell apoptosis and autophagy-related cell death. In vivo studies confirmed that 21y strongly inhibited tumor growth and lung metastasis in breast cancer. Taken together, 21y targets ERK1/2 as a promising therapeutic agent for breast cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UreaAntineoplastic AgentsImidazolesApoptosisHumansAnimalsFemaleMiceMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Cell Line, TumorMice, NudeCell ProliferationStructure-Activity RelationshipProtein Kinase InhibitorsMice, Inbred BALB CDrug Screening Assays, AntitumorDrug DiscoveryMAP Kinase Signaling System

Substanzen

UreaAntineoplastic AgentsImidazolesMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Protein Kinase Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, NMPA Key Laboratory for Research and Evaluation of Innovative Drug, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, Henan 45…

ORCID-Profile: Junbiao Chang, Bo Zhu

Förderung

  • Central Plains Scholars and Scientists Studio Fund
  • Henan Key Laboratory of Organic Functional Molecules and Drug Innovation
  • National Natural Science Foundation of China
  • Science and Technology Major Project of Henan Province
  • Research Project from Pingyuan Laboratory

Zitieren

APA

Wang, M., Yang, S., Li, X., Zheng, Y., Bai, Y., Luo, W., Zhu, G., Chang, J., & Zhu, B. (2025). Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01434

Vancouver

Wang M, Yang S, Li X, Zheng Y, Bai Y, Luo W, et al. Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c01434

BibTeX
@article{Wang2025,
  author = {Wang, Mengqi and Yang, Shuping and Li, Xinge and Zheng, Yingying and Bai, Yan and Luo, Wenhan and Zhu, Gongming and Chang, Junbiao and Zhu, Bo},
  title = {Discovery of Novel Aromatic Urea-Imidazole Salt Derivatives for Cancer Therapy via Targeting ERK1/2},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c01434}
}
Kostenlos starten →